This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
by Zacks Equity Research
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $88.11, moving +0.27% from the previous trading session.
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
by Zacks Equity Research
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
by Zacks Equity Research
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
by Zacks Equity Research
FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $94.02, denoting a -0.74% change from the preceding trading day.
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
by Ekta Bagri
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
Merck (MRK) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $94.71, denoting a +1.46% change from the preceding trading day.
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $93.43, moving -1.37% from the previous trading session.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
by Zacks Equity Research
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.
Zacks Investment Ideas feature highlights: Molson Coors, Merck & Co. and Deutsche Telekom
by Zacks Equity Research
Molson Coors, Merck & Co. and Deutsche Telekom are part of the Zacks Investment Ideas article.
Safe Haven Stocks: 3 Top Picks for Navigating Volatility
by Ethan Feller
Merck and Co., Molson Coors and Deutsche Telekom all show defensive characteristics and bullish catalysts amid market turmoil
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?
by Ekta Bagri
BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook for 2025 is weak. We recommend investors to wait.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Merck (MRK) closed at $94 in the latest trading session, marking a +0.87% move from the prior day.
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Merck (MRK) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $92.25, moving +1.84% from the previous trading session.
Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More
by Kinjel Shah
LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.